Assenagon Asset Management
VYNE icon

Assenagon Asset Management’s VYNE Therapeutics VYNE Stock Holding History

Assenagon Asset Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-900
Closed -$388K – 1088
2019
Q2 		$388K Buy
+900
New +$445K ﹤0.01% 883

Other funds holding VYNE

First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Assenagon Asset Management's VYNE Position: Q3 2019 in Review

Assenagon Asset Management sold out of VYNE Therapeutics (VYNE) in Q3 2019, closing a stake of 900 shares — an estimated $388K sold.

Assenagon Asset Management first reported a position in VYNE in Q2 2019 and held it in 1 quarter. The position peaked at $388K in Q2 2019. 55 funds tracked by Wall St. Rank hold VYNE as of Q3 2019.

  • Assenagon Asset Management reported no remaining VYNE Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Assenagon Asset Management sold 900 VYNE Therapeutics shares in Q3 2019, an estimated $388K.
  • Assenagon Asset Management first reported a position in VYNE Therapeutics in Q2 2019 and held it in 1 quarter.
  • Assenagon Asset Management's VYNE Therapeutics position peaked at $388K in Q2 2019.
  • 55 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2019.

Based on Assenagon Asset Management's 13F filing for Q3 2019, filed 16 Oct 2019.